Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
Author/Authors :
John A Baron، نويسنده , , Robert S Sandler، نويسنده , , Robert S Bresalier، نويسنده , , Angel Lanas، نويسنده , , Dion G Morton، نويسنده , , Robert Riddell، نويسنده , , Erik R Iverson، نويسنده , , David L. DeMets، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
9
From page :
1756
To page :
1764
Abstract :
Summary
Background
Selective inhibition of cyclo-oxygenase-2 has been associated with an increased risk of cardiovascular events in several clinical trials. The Adenomatous Polyp Prevention on Vioxx (APPROVe) study assessed the effect of 3-year treatment
